{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T18:18:27Z","timestamp":1783793907772,"version":"3.55.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"DOI":"10.1007\/s11906-025-01352-5","type":"journal-article","created":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T09:47:11Z","timestamp":1766828831000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Obesity in Cardiorenal syndrome: Management Opportunities and Challenges"],"prefix":"10.1007","volume":"28","author":[{"given":"Allison","family":"Reaves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Jaffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"McCallum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,27]]},"reference":[{"key":"1352_CR1","unstructured":"Centers for Disease Control and Prevention. Adult Obesity Prevalence Maps. U.S. Dept of Health and Human Services; 2023. https:\/\/www.cdc.gov\/obesity\/data-and-statistics\/adult-obesity-prevalence-maps.html. Accessed 16 Sept 2025."},{"issue":"2","key":"1352_CR2","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41366-024-01668-3","volume":"49","author":"J G\u00f3mez-Ambrosi","year":"2025","unstructured":"G\u00f3mez-Ambrosi J, Catal\u00e1n V, Fr\u00fchbeck G. The evolution of the understanding of obesity over the last 100 years. Int J Obes. 2025;49(2):168\u201376. https:\/\/doi.org\/10.1038\/s41366-024-01668-3.","journal-title":"Int J Obes"},{"issue":"3","key":"1352_CR3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","volume":"13","author":"F Rubino","year":"2025","unstructured":"Rubino F, Cummings DE, Eckel RH, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13(3):221\u201362. https:\/\/doi.org\/10.1016\/S2213-8587(24)00316-4.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1352_CR4","unstructured":"Obesity and overweight. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight. Accessed 16 Oct 2025."},{"issue":"15","key":"1352_CR5","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1001\/archinternmed.2010.201","volume":"170","author":"EJ Jacobs","year":"2010","unstructured":"Jacobs EJ, Newton CC, Wang Y, et al. Waist circumference and all-cause mortality in a large US cohort. Arch Intern Med. 2010;170(15):1293\u2013301. https:\/\/doi.org\/10.1001\/archinternmed.2010.201.","journal-title":"Arch Intern Med"},{"issue":"5","key":"1352_CR6","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.ekir.2025.03.022","volume":"10","author":"TB Drueke","year":"2025","unstructured":"Drueke TB, Wiecek A, Massy ZA. New obesity guidelines and implications for CKD. Kidney Int Rep. 2025;10(5):1305\u20138. https:\/\/doi.org\/10.1016\/j.ekir.2025.03.022.","journal-title":"Kidney Int Rep"},{"issue":"20","key":"1352_CR7","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation. 2023;148(20):1606\u201335. https:\/\/doi.org\/10.1161\/CIR.0000000000001184.","journal-title":"Circulation"},{"issue":"3","key":"1352_CR8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1152\/physiol.00037.2016","volume":"32","author":"MTJ Sch\u00fctten","year":"2017","unstructured":"Sch\u00fctten MTJ, Houben AJHM, de Leeuw PW, Stehouwer CDA. The link between adipose tissue renin-angiotensin-aldosterone system signaling and obesity-associated hypertension. Physiology. 2017;32(3):197\u2013209. https:\/\/doi.org\/10.1152\/physiol.00037.2016.","journal-title":"Physiology"},{"issue":"6","key":"1352_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0178672","volume":"12","author":"H Uemura","year":"2017","unstructured":"Uemura H, Katsuura-Kamano S, Yamaguchi M, et al. Relationships of serum high-sensitivity C-reactive protein and body size with insulin resistance in a Japanese cohort. PLoS One. 2017;12(6):e0178672. https:\/\/doi.org\/10.1371\/journal.pone.0178672.","journal-title":"PLoS One"},{"key":"1352_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2019.01607","author":"F Zatterale","year":"2020","unstructured":"Zatterale F, Longo M, Naderi J, et al. Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes. Front Physiol. 2020. https:\/\/doi.org\/10.3389\/fphys.2019.01607.","journal-title":"Front Physiol"},{"issue":"8","key":"1352_CR11","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1210\/jcem.83.8.5026","volume":"83","author":"P Dandona","year":"1998","unstructured":"Dandona P, Weinstock R, Thusu K, Abdel-Rahman E, Aljada A, Wadden T. Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab. 1998;83(8):2907\u201310. https:\/\/doi.org\/10.1210\/jcem.83.8.5026.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"1352_CR12","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/s0026-0495(99)90277-9","volume":"48","author":"C Tsigos","year":"1999","unstructured":"Tsigos C, Kyrou I, Chala E, et al. Circulating tumor necrosis factor alpha concentrations are higher in abdominal versus peripheral obesity. Metabolism. 1999;48(10):1332\u20135. https:\/\/doi.org\/10.1016\/s0026-0495(99)90277-9.","journal-title":"Metabolism"},{"issue":"11","key":"1352_CR13","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00011-009-0060-4","volume":"58","author":"K Eder","year":"2009","unstructured":"Eder K, Baffy N, Falus A, Fulop AK. The major inflammatory mediator interleukin-6 and obesity. Inflamm Res. 2009;58(11):727\u201336. https:\/\/doi.org\/10.1007\/s00011-009-0060-4.","journal-title":"Inflamm Res"},{"issue":"17","key":"1352_CR14","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1161\/CIRCULATIONAHA.114.015000","volume":"132","author":"TM Abraham","year":"2015","unstructured":"Abraham TM, Pedley A, Massaro JM, Hoffmann U, Fox CS. Association between visceral and subcutaneous adipose depots and incident cardiovascular disease risk factors. Circulation. 2015;132(17):1639\u201347. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.015000.","journal-title":"Circulation"},{"issue":"10","key":"1352_CR15","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.jchf.2023.06.027","volume":"11","author":"EM Boorsma","year":"2023","unstructured":"Boorsma EM, Sorimachi H, Ter Maaten JM, et al. Perirenal adipose tissue is associated with renal dysfunction and abnormal hemodynamics in patients with HFpEF. JACC: Heart Failure. 2023;11(10):1463\u20135. https:\/\/doi.org\/10.1016\/j.jchf.2023.06.027.","journal-title":"JACC: Heart Failure"},{"issue":"12","key":"1352_CR16","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1038\/oby.2008.418","volume":"16","author":"BS Mohammed","year":"2008","unstructured":"Mohammed BS, Cohen S, Reeds D, Young VL, Klein S. Long-term effects of large-volume liposuction on metabolic risk factors for coronary heart disease. Obesity. 2008;16(12):2648\u201351. https:\/\/doi.org\/10.1038\/oby.2008.418.","journal-title":"Obesity"},{"issue":"6","key":"1352_CR17","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1681\/ASN.2005060638","volume":"17","author":"E Ejerblad","year":"2006","unstructured":"Ejerblad E, Fored CM, Lindblad P, Fryzek J, McLaughlin JK, Nyr\u00e9n O. Obesity and risk for chronic renal failure. J Am Soc Nephrol. 2006;17(6):1695\u2013702. https:\/\/doi.org\/10.1681\/ASN.2005060638.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"1352_CR18","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/oby.22134","volume":"26","author":"AR Chang","year":"2018","unstructured":"Chang AR, Surapaneni A, Kirchner HL, et al. Metabolically healthy obesity and risk of kidney function decline. Obesity. 2018;26(4):762\u20138. https:\/\/doi.org\/10.1002\/oby.22134.","journal-title":"Obesity"},{"issue":"1","key":"1352_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.7326\/0003-4819-144-1-200601030-00006","volume":"144","author":"C Hsu","year":"2006","unstructured":"Hsu C, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144(1):21\u20138. https:\/\/doi.org\/10.7326\/0003-4819-144-1-200601030-00006.","journal-title":"Ann Intern Med"},{"issue":"25","key":"1352_CR20","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003769","volume":"95","author":"Y He","year":"2016","unstructured":"He Y, Li F, Wang F, Ma X, Zhao X, Zeng Q. The association of chronic kidney disease and waist circumference and waist-to-height ratio in Chinese urban adults. Medicine (Baltimore). 2016;95(25):e3769. https:\/\/doi.org\/10.1097\/MD.0000000000003769.","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"1352_CR21","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.008507","volume":"7","author":"SAE Peters","year":"2018","unstructured":"Peters SAE, Bots SH, Woodward M. Sex differences in the association between measures of general and central adiposity and the risk of myocardial infarction: results from the UK Biobank. J Am Heart Assoc. 2018;7(5):e008507. https:\/\/doi.org\/10.1161\/JAHA.117.008507.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"1352_CR22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1161\/CIRCULATIONAHA.116.021884","volume":"134","author":"SJ Shah","year":"2016","unstructured":"Shah SJ, Kitzman DW, Borlaug BA, et al. Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation. 2016;134(1):73\u201390. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.021884.","journal-title":"Circulation"},{"issue":"12","key":"1352_CR23","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jchf.2018.07.009","volume":"6","author":"VN Rao","year":"2018","unstructured":"Rao VN, Zhao D, Allison MA, et al. Adiposity and Incident Heart Failure and its Subtypes: MESA (Multi-Ethnic Study of Atherosclerosis). JACC Heart Fail. 2018;6(12):999\u20131007. https:\/\/doi.org\/10.1016\/j.jchf.2018.07.009.","journal-title":"JACC Heart Fail"},{"issue":"1","key":"1352_CR24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","volume":"136","author":"M Obokata","year":"2017","unstructured":"Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation. 2017;136(1):6\u201319. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.026807.","journal-title":"Circulation"},{"issue":"2","key":"1352_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.cardfail.2019.09.015","volume":"26","author":"YNV Reddy","year":"2020","unstructured":"Reddy YNV, Obokata M, Testani JM, et al. Adverse renal response to decongestion in the obese phenotype of heart failure with preserved ejection fraction. J Card Fail. 2020;26(2):101\u20137. https:\/\/doi.org\/10.1016\/j.cardfail.2019.09.015.","journal-title":"J Card Fail"},{"issue":"1\u20133","key":"1352_CR26","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.regpep.2008.10.010","volume":"153","author":"T Nishikimi","year":"2009","unstructured":"Nishikimi T, Iemura-Inaba C, Akimoto K, Ishikawa K, Koshikawa S, Matsuoka H. Stimulatory and inhibitory regulation of lipolysis by the NPR-A\/cGMP\/PKG and NPR-C\/G(i) pathways in rat cultured adipocytes. Regul Pept. 2009;153(1\u20133):56\u201363. https:\/\/doi.org\/10.1016\/j.regpep.2008.10.010.","journal-title":"Regul Pept"},{"issue":"9","key":"1352_CR27","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1373\/clinchem.2019.302547","volume":"65","author":"LK Lewis","year":"2019","unstructured":"Lewis LK, Raudsepp SD, Prickett TCR, et al. ProBNP that is not glycosylated at threonine 71 is decreased with obesity in patients with heart failure. Clin Chem. 2019;65(9):1115\u201324. https:\/\/doi.org\/10.1373\/clinchem.2019.302547.","journal-title":"Clin Chem"},{"issue":"4","key":"1352_CR28","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"PE Stevens","year":"2024","unstructured":"Stevens PE, Ahmed SB, Carrero JJ, et al. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4):S117\u2013314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018.","journal-title":"Kidney Int"},{"issue":"12","key":"1352_CR29","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.numecd.2016.09.003","volume":"26","author":"YY Hyun","year":"2016","unstructured":"Hyun YY, Lee KB, Rhee EJ, Park CY, Chang Y, Ryu S. Chronic kidney disease and high eGFR according to body composition phenotype in adults with normal BMI. Nutr Metab Cardiovasc Dis. 2016;26(12):1088\u201395. https:\/\/doi.org\/10.1016\/j.numecd.2016.09.003.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"12","key":"1352_CR30","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.2215\/CJN.02140214","volume":"9","author":"D Sharma","year":"2014","unstructured":"Sharma D, Hawkins M, Abramowitz MK. Association of sarcopenia with eGFR and misclassification of obesity in adults with CKD in the United States. Clin J Am Soc Nephrol. 2014;9(12):2079\u201388. https:\/\/doi.org\/10.2215\/CJN.02140214.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"1352_CR31","doi-asserted-by":"publisher","first-page":"742","DOI":"10.2215\/CJN.0000000704","volume":"20","author":"CP Kovesdy","year":"2025","unstructured":"Kovesdy CP. Obesity and metabolic health in CKD. Clin J Am Soc Nephrol. 2025;20(5):742\u201354. https:\/\/doi.org\/10.2215\/CJN.0000000704.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"1352_CR32","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1097\/MCO.0000000000000871","volume":"25","author":"MI Barreto Silva","year":"2022","unstructured":"Barreto Silva MI, Picard K, Klein MRST. Sarcopenia and sarcopenic obesity in chronic kidney disease: update on prevalence, outcomes, risk factors and nutrition treatment. Curr Opin Clin Nutr Metab Care. 2022;25(6):371\u20137. https:\/\/doi.org\/10.1097\/MCO.0000000000000871.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"3","key":"1352_CR33","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/eurjpc\/zwae279","volume":"32","author":"KC Koskinas","year":"2025","unstructured":"Koskinas KC, Van Craenenbroeck EM, Antoniades C, et al. Obesity and cardiovascular disease: an ESC clinical consensus statement. Eur J Prev Cardiol. 2025;32(3):184\u2013220. https:\/\/doi.org\/10.1093\/eurjpc\/zwae279.","journal-title":"Eur J Prev Cardiol"},{"issue":"18","key":"1352_CR34","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/j.jacc.2025.03.009","volume":"85","author":"M Packer","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, et al. Interplay of chronic kidney disease and the effects of Tirzepatide in patients with heart failure, preserved ejection fraction, and obesity. J Am Coll Cardiol. 2025;85(18):1721\u201335. https:\/\/doi.org\/10.1016\/j.jacc.2025.03.009.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"1352_CR35","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1038\/oby.2009.96","volume":"17","author":"N Naour","year":"2009","unstructured":"Naour N, Fellahi S, Renucci JF, et al. Potential contribution of adipose tissue to elevated serum cystatin C in human obesity. Obesity. 2009;17(12):2121\u20136. https:\/\/doi.org\/10.1038\/oby.2009.96.","journal-title":"Obesity"},{"issue":"3","key":"1352_CR36","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/cpt.729","volume":"102","author":"AS Levey","year":"2017","unstructured":"Levey AS, Inker LA. Assessment of glomerular filtration rate in health and disease: a state of the art review. Clin Pharmacol Ther. 2017;102(3):405\u201319. https:\/\/doi.org\/10.1002\/cpt.729.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"1352_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.xgen.2023.100347","volume":"3","author":"SO Kleeman","year":"2023","unstructured":"Kleeman SO, Thakir TM, Demestichas B, et al. Cystatin C is glucocorticoid responsive, directs recruitment of Trem2+ macrophages, and predicts failure of cancer immunotherapy. Cell Genom. 2023;3(8):100347. https:\/\/doi.org\/10.1016\/j.xgen.2023.100347.","journal-title":"Cell Genom"},{"issue":"10","key":"1352_CR38","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/s41574-025-01160-6","volume":"21","author":"F Sanchis-Gomar","year":"2025","unstructured":"Sanchis-Gomar F, Neeland IJ, Lavie CJ. Balancing weight and muscle loss in GLP1 receptor agonist therapy. Nat Rev Endocrinol. 2025;21(10):584\u20135. https:\/\/doi.org\/10.1038\/s41574-025-01160-6.","journal-title":"Nat Rev Endocrinol"},{"issue":"4S","key":"1352_CR39","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"KDIGO","year":"2024","unstructured":"KDIGO. Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117-314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018.","journal-title":"Kidney Int"},{"issue":"5","key":"1352_CR40","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025;392(5):427\u201337. https:\/\/doi.org\/10.1056\/NEJMoa2410027.","journal-title":"N Engl J Med"},{"issue":"12","key":"1352_CR41","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069\u201384. https:\/\/doi.org\/10.1056\/NEJMoa2306963.","journal-title":"N Engl J Med"},{"issue":"2","key":"1352_CR42","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41591-024-03374-z","volume":"31","author":"BA Borlaug","year":"2025","unstructured":"Borlaug BA, Zile MR, Kramer CM, et al. Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial. Nat Med. 2025;31(2):544\u201351. https:\/\/doi.org\/10.1038\/s41591-024-03374-z.","journal-title":"Nat Med"},{"issue":"24","key":"1352_CR43","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2307563.","journal-title":"N Engl J Med"},{"issue":"7","key":"1352_CR44","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","volume":"30","author":"HM Colhoun","year":"2024","unstructured":"Colhoun HM, Lingvay I, Brown PM, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med. 2024;30(7):2058\u201366. https:\/\/doi.org\/10.1038\/s41591-024-03015-5.","journal-title":"Nat Med"},{"issue":"11","key":"1352_CR45","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1681\/ASN.0000000512","volume":"35","author":"TA Ikizler","year":"2024","unstructured":"Ikizler TA, Kramer HJ, Beddhu S, et al. ASN kidney health guidance on the management of obesity in persons living with kidney diseases. J Am Soc Nephrol. 2024;35(11):1574\u201388. https:\/\/doi.org\/10.1681\/ASN.0000000512.","journal-title":"J Am Soc Nephrol"},{"key":"1352_CR46","unstructured":"Drugs@FDA: FDA-Approved Drugs. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=200063. Accessed 26 Sept 2025."},{"key":"1352_CR47","unstructured":"Controversial Study Evaluating Cardiovascular Safety Of Anti-Obesity Drug Is Inconclusive. Cleveland Clinic. https:\/\/newsroom.clevelandclinic.org\/2016\/03\/08\/controversial-study-evaluating-cardiovascular-safety-anti-obesity-drug-inconclusive. Accessed 26 Sept 2025."},{"key":"1352_CR48","unstructured":"Drugs@FDA: FDA-Approved Drugs. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=020766. Accessed 26 Sept 2025."},{"key":"1352_CR49","unstructured":"Drugs@FDA: FDA-Approved Drugs. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=022580. Accessed 26 Sept 2025."},{"issue":"5","key":"1352_CR50","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.13172","volume":"7","author":"D Do","year":"2024","unstructured":"Do D, Lee T, Peasah SK, Good CB, Inneh A, Patel U. GLP-1 receptor agonist discontinuation among patients with obesity and\/or type 2 diabetes. JAMA Netw Open. 2024;7(5):e2413172. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.13172.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"1352_CR51","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.57349","volume":"8","author":"PJ Rodriguez","year":"2025","unstructured":"Rodriguez PJ, Zhang V, Gratzl S, et al. Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity. JAMA Netw Open. 2025;8(1):e2457349. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.57349.","journal-title":"JAMA Netw Open"},{"key":"1352_CR52","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2025.3590","author":"TS Barrett","year":"2025","unstructured":"Barrett TS, Hafermann JO, Richards S, LeJeune K, Eid GM. Obesity treatment with bariatric surgery vs GLP-1 receptor agonists. JAMA Surg. 2025. https:\/\/doi.org\/10.1001\/jamasurg.2025.3590.","journal-title":"JAMA Surg"},{"issue":"7","key":"1352_CR53","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1007\/s00464-024-10983-9","volume":"38","author":"K Abi Mosleh","year":"2024","unstructured":"Abi Mosleh K, Sample JW, Belluzzi A, et al. Bariatric surgery and the diseased kidney: a 5-year assessment of safety and postoperative renal outcomes. Surg Endosc. 2024;38(7):4014\u201323. https:\/\/doi.org\/10.1007\/s00464-024-10983-9.","journal-title":"Surg Endosc"},{"issue":"1","key":"1352_CR54","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s11695-024-07612-8","volume":"35","author":"N Einafshar","year":"2025","unstructured":"Einafshar N, Esparham A, Moghani MS, Radboy M, Ghamari MJ, Zandbaf T. The impact of metabolic and bariatric surgery on diabetic kidney disease in patients with type 2 diabetes: a systematic review and meta-analysis. Obes Surg. 2025;35(1):329\u201340. https:\/\/doi.org\/10.1007\/s11695-024-07612-8.","journal-title":"Obes Surg"},{"issue":"5","key":"1352_CR55","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1001\/jamasurg.2017.5025","volume":"153","author":"AP Courcoulas","year":"2018","unstructured":"Courcoulas AP, King WC, Belle SH, et al. Seven-year weight trajectories and health outcomes in the longitudinal assessment of bariatric surgery (LABS) study. JAMA Surg. 2018;153(5):427\u201334. https:\/\/doi.org\/10.1001\/jamasurg.2017.5025.","journal-title":"JAMA Surg"},{"issue":"1","key":"1352_CR56","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/jama.2011.1914","volume":"307","author":"L Sj\u00f6str\u00f6m","year":"2012","unstructured":"Sj\u00f6str\u00f6m L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012;307(1):56\u201365. https:\/\/doi.org\/10.1001\/jama.2011.1914.","journal-title":"JAMA"},{"key":"1352_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.05.008","author":"MM Kittleson","year":"2025","unstructured":"Kittleson MM, Benjamin EJ, Blumer V, et al. 2025 ACC scientific statement on the management of obesity in adults with heart failure. JACC. 2025. https:\/\/doi.org\/10.1016\/j.jacc.2025.05.008.","journal-title":"JACC"},{"key":"1352_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.155931","author":"Y Handelsman","year":"2024","unstructured":"Handelsman Y, Anderson JE, Bakris GL, et al. DCRM 2.0: multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Metabolism. 2024. https:\/\/doi.org\/10.1016\/j.metabol.2024.155931.","journal-title":"Metabolism"},{"issue":"8","key":"1352_CR59","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1002\/oby.24336","volume":"33","author":"D Mozaffarian","year":"2025","unstructured":"Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity. 2025;33(8):1475\u2013503. https:\/\/doi.org\/10.1002\/oby.24336.","journal-title":"Obesity"},{"key":"1352_CR60","unstructured":"Association NG. Food is Medicine: A Strategic Shift in State Health Policy. National Governors Association. June 17, 2025. https:\/\/www.nga.org\/news\/commentary\/food-as-medicine-a-strategic-shift-in-state-health-policy\/. Accessed 1 Oct 2025."},{"key":"1352_CR61","unstructured":"kfflizw. Medicaid Coverage of and Spending on GLP-1s. KFF. November 4, 2024. https:\/\/www.kff.org\/medicaid\/medicaid-coverage-of-and-spending-on-glp-1s\/. Accessed 1 Oct 2025."},{"issue":"23","key":"1352_CR62","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1509225.","journal-title":"N Engl J Med"},{"issue":"11","key":"1352_CR63","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S2213-8587(18)30268-7","volume":"6","author":"MHA Muskiet","year":"2018","unstructured":"Muskiet MHA, Tonneijck L, Huang Y, et al. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2018;6(11):859\u201369. https:\/\/doi.org\/10.1016\/S2213-8587(18)30268-7.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"1352_CR64","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1603827.","journal-title":"N Engl J Med"},{"issue":"9","key":"1352_CR65","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1056\/NEJMoa1616011","volume":"377","author":"JFE Mann","year":"2017","unstructured":"Mann JFE, \u00d8rsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377(9):839\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1616011.","journal-title":"N Engl J Med"},{"issue":"19","key":"1352_CR66","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1607141.","journal-title":"N Engl J Med"},{"issue":"13","key":"1352_CR67","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1612917.","journal-title":"N Engl J Med"},{"issue":"2","key":"1352_CR68","doi-asserted-by":"publisher","first-page":"446","DOI":"10.2337\/dc19-1065","volume":"43","author":"MA Bethel","year":"2020","unstructured":"Bethel MA, Mentz RJ, Merrill P, et al. Microvascular and cardiovascular outcomes according to renal function in patients treated with once-weekly exenatide: insights from the EXSCEL trial. Diabetes Care. 2020;43(2):446\u201352. https:\/\/doi.org\/10.2337\/dc19-1065.","journal-title":"Diabetes Care"},{"issue":"20","key":"1352_CR69","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1161\/CIRCULATIONAHA.119.041659","volume":"140","author":"M Fudim","year":"2019","unstructured":"Fudim M, White J, Pagidipati NJ, et al. Effect of once-weekly exenatide in patients with type 2 diabetes mellitus with and without heart failure and heart failure-related outcomes: insights from the EXSCEL trial. Circulation. 2019;140(20):1613\u201322. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.041659.","journal-title":"Circulation"},{"issue":"10193","key":"1352_CR70","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3.","journal-title":"Lancet"},{"issue":"9","key":"1352_CR71","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841\u201351. https:\/\/doi.org\/10.1056\/NEJMoa1901118.","journal-title":"N Engl J Med"},{"issue":"4","key":"1352_CR72","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.kint.2022.12.028","volume":"103","author":"KR Tuttle","year":"2023","unstructured":"Tuttle KR, Bosch-Traberg H, Cherney DZI, et al. Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo. Kidney Int. 2023;103(4):772\u201381. https:\/\/doi.org\/10.1016\/j.kint.2022.12.028.","journal-title":"Kidney Int"},{"issue":"7","key":"1352_CR73","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","volume":"30","author":"HM Colhoun","year":"2024","unstructured":"Colhoun HM, Lingvay I, Brown PM, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med. 2024;30(7):2058\u201366. https:\/\/doi.org\/10.1038\/s41591-024-03015-5.","journal-title":"Nat Med"},{"issue":"2","key":"1352_CR74","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2403347.","journal-title":"N Engl J Med"},{"issue":"18","key":"1352_CR75","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/j.jacc.2025.03.009","volume":"85","author":"M Packer","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, et al. Interplay of chronic kidney disease and the effects of Tirzepatide in patients with heart failure, preserved ejection fraction, and obesity: the SUMMIT trial. J Am Coll Cardiol. 2025;85(18):1721\u201335. https:\/\/doi.org\/10.1016\/j.jacc.2025.03.009.","journal-title":"J Am Coll Cardiol"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-025-01352-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11906-025-01352-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-025-01352-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T09:47:13Z","timestamp":1766828833000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11906-025-01352-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,27]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1352"],"URL":"https:\/\/doi.org\/10.1007\/s11906-025-01352-5","relation":{},"ISSN":["1534-3111"],"issn-type":[{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,27]]},"assertion":[{"value":"2 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"1"}}